FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new compound presented by general formula 
(I) where values of Rx, R3, R4, X and A substitutes are described in the patent claim, inhibiting tyrosine kinase of EGF receptor and HER2 tyrosine kinase, as well as to using the compound of formula (I) and pharmaceutical composition containing this compound or its pharmaceutically acceptable salt.
EFFECT: preparation of the tyrosine kinase inhibiting compound.
14 cl, 19 ex, 53 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PURINE DERIVATIVES AS A RECEPTOR AGONISTS | 2006 |
|
RU2400483C2 |
| NOVEL DERIVATIVES OF IMIDAZOLIDINE, THEIR PREPARING, THEIR APPLICATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF | 1998 |
|
RU2213737C2 |
| OBTAINING DIHYDROTHIENO[3,2-d]PYRIMIDINES AND INTERMEDIATE PRODUCTS, APPLIED FOR THEIR SYNTHESIS | 2008 |
|
RU2528340C2 |
| PURINE DERIVATIVES FOR APPLICATION AS AGONISTS OF ADENOSINE RECEPTOR A-2A | 2005 |
|
RU2403253C2 |
| FIVE-MEMBERED HETEROCYCLES AS INHIBITORS OF LEUKOCYTE ADHESION AND VLA-4 ANTAGONISTS | 1997 |
|
RU2229296C2 |
| CONDENSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOUR NECROSIS FACTOR-ALFA | 2005 |
|
RU2406724C2 |
| CONDENSED HETEROCYCLIC COMPOUND | 2009 |
|
RU2480473C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| HETEROARYL-SUBSTITUTED AMIDES CONTAINING SATURATED BINDING GROUP AND USE THEREOF AS PHARMACEUTICAL AGENTS | 2006 |
|
RU2412181C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
